Improving immune response in lung cancer by targeting low oxygen levels in tumors
Targeting mitochondrial oxygen demand to overcome hypoxic immune privilege of NSCLC tumors
This study is looking at how low oxygen levels in lung cancer tumors can make it harder for the immune system to fight the cancer, and it aims to find new ways to boost the immune response to improve treatment options for patients with non-small cell lung cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10808602 on NIH RePORTER |
What this research studies
This research investigates how low oxygen levels in non-small cell lung cancer (NSCLC) tumors affect the immune system's ability to fight cancer. It focuses on understanding the mechanisms behind treatment resistance and aims to develop new therapies that can enhance the effectiveness of existing immunotherapies. By studying the behavior of immune cells in the hypoxic tumor environment, the research seeks to identify ways to improve immune cell function and increase their infiltration into tumors. Patients may benefit from novel treatment strategies that could lead to better outcomes in managing NSCLC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are experiencing treatment resistance.
Not a fit: Patients with other types of lung cancer or those who are not currently undergoing treatment for NSCLC may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with non-small cell lung cancer, potentially increasing survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in targeting tumor hypoxia to enhance immune responses, suggesting that this approach could be effective in NSCLC as well.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Benej, Martin — Ohio State University
- Study coordinator: Benej, Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.